American Journal of Health Research

Special Issue

Mycobacterial Drug Resistance

  • Submission Deadline: Apr. 30, 2016
  • Status: Submission Closed
  • Lead Guest Editor: Anand Kumar Maurya
About This Special Issue
Tuberculosis (TB) remains one of the leading causes of morbidity and mortality worldwide, and resistance to commonly used antituberculous drugs is increasing. DR-TB is a major threat to global public health as it is difficult to treat and often results in relapse or treatment failure. It is also a risk factor for the emergence of Multidrug-resistant tuberculosis (MDR-TB) that does not respond to at least isoniazid and rifampicin and Extensively drug-resistant TB (XDR-TB) defined as infection with MDR-TB strains additionally resistant either to a new-generation fluoroquinolone and an injectable agent or to three of the six main classes of second-line drugs.

The diagnosis of MDR and XDR TB is based on mycobacterial culture and drug susceptibility testing on liquid or solid media, with results available in weeks to months. To address such delay in TB diagnosis as well as to discretely improve the diagnosis accuracy, early detection of DR-TB allows starting of a proper treatment, which has an impact in the better control of the disease. Rapid molecular methods are available for detecting drug-resistant TB, shorter turnaround time, no need for growth of the organism, possibility for direct application in clinical samples, less biohazard risks, and feasibility for automation.

The aim of special issue is to collect excellence of latest research contributions in the field of Mycobacterial Drug Resistance. We are interested in Original research, Review, Short communications, Short reports, Technical notes, case reports and others are solicited in the following areas:

1. Epidemiology of DR-TB
2. Biologic and Molecular mechanism of DR-TB
3. Diagnosis of DR-TB: Conventional and Genotypic Methods
4. Potential Causes and Predictors for The Development of DR-TB
5. Newer Diagnostics for Technologies and Tools for DR-TB
6. Treatment and management of DR-TB
7. Prevention of nosocomial transmission of DR-TB
8. Newer anti-TB drugs for DR-TB
9. TB and HIV Co-Infection
10. Tuberculosis Infection and Reinfection
11. Immunology in Tuberculosis
12. Advances in Tuberculosis Research
13. Molecular epidemiology
14. Vaccine development
15. Antimicrobial Susceptibility Testing and Therapy of Infections with Nontuberculous Mycobacteria
Lead Guest Editor
  • Anand Kumar Maurya

    Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, India

Guest Editors
  • S.M. Wasiur Rahman

    Qatif Central Hospital, Ministory of Health, Dammam, Saudi Arabia

  • Santosh Kumar

    Department of Biosciences, University of Texas, Texas, United States

  • Vikram Saini

    Department of Microbiology, University of Alabama at Birmingham, Birmingham, United States

  • Kranthi Kunkalla

    Department of Hematopathology, University of Miami, Miami, United States

  • Fahriye Keskin

    Department of Microbiology, Dentistry Faculty, Istanbul University, Istanbul, Turkey

  • Ameer Khusro

    Department of Plant Biology and Biotechnology, Loyola College, University of Madras, Chennai, India

  • Vijaya Lakshmi Nag

    Department of Microbiology, All India Institute of Medical Sciences, Jodhpur, India

  • Surya Kant

    Department of Pulmonary Medicine, King George’s Medical University, Lucknow, India

  • Ram Awadh Singh Kushwaha

    Department of Pulmonary Medicine, King George’s Medical University, Lucknow, India

  • Amresh Kumar Singh

    Department of Microbiology, BRD Medical College, Gorakhpur, India

  • Mikiyas Amare Getu

    Department of Nursing, Woldia University, Woldia, Ethiopia